Medivir’s Cold Sore Treatment Xerese™ Now Launched in the United States

Huddinge, Sweden - Medivir AB (OMX: MVIR), the emerging research-based specialty pharmaceutical company focused on infectious diseases, today announces that the Company’s commercialization partner, Meda AB, has launched Medivir’s unique cold sore treatment Xerese™ in the United States. Xerese™ is the first topical combination product of five per cent acyclovir and one per cent hydrocortisone in a unique cream vehicle for the treatment of recurrent herpes simplex labialis.  Xerese™ was granted FDA marketing approval [1] and based on strong clinical data, Xerese™ was given a label, which